Key result
Cilazapril reduces ST depression and prolongs exercise time vs. placebo in syndrome X.
Why the study?
The pathophysiology of syndrome X is unclear, and the effect of long-term cilazapril treatment on this condition was investigated.
RCT (n=18)
Double-blind
Randomized crossover
Answers are grounded in this paper and cite their sources.
Cilazapril may improve exercise tolerance in syndrome X; extends limited randomized evidence for ACE inhibitors in microvascular angina.
OBJECTIVES: Although the pathophysiology of syndrome X (angina pectoris, positive ECG test findings and normal coronary arteriogram) is unclear, it is generally accepted that intracellular metabolic changes resulting from abnormal constriction of prearteriolar vessels due to endothelium-dependent vasodilation abnormalities may play a role in the pathogenesis. We established the effect of long-term treatment with cilazapril, an angiotensin-converting enzyme inhibitor, which prevents the effect of angiotensin II in the tonic control of vascular resistance. METHODS: 18 patients (15 women and 3 men, mean age 43.2 +/- 4.6 years) with syndrome X were included in this study. A randomized double-blind crossover placebo-controlled trial was done. After a 1-week washout period, patients received either cilazapril 2 x 2.5 mg or placebo for 3 weeks, followed by 3 weeks of the other therapy. At the end of two periods, an exercise ECG test (modified Bruce protocol) was employed. RESULTS: The magnitude of ST segment depression was significantly decreased during treatment with cilazapril compared with placebo. On the other hand, total exercise time and time to 1 mm ST segment depression were significantly prolonged by cilazapril. However, rate pressure products were not significantly different at peak exercise at or at 1 mm of ST segment depression during both therapies. CONCLUSION: Cilazapril exerted a beneficial therapeutic effect in cases with syndrome X. The possible mechanism of this effect may be a modulation of coronary tone at the microcirculation level.
No takes yet. Share an insight, caveat, or question.
Nalbantgil et al. (1998) conducted an RCT in Syndrome X (n=18). Cilazapril vs. Placebo was evaluated on Magnitude of ST segment depression and exercise time on ECG test. In a crossover trial of 18 patients with syndrome X, 3 weeks of cilazapril significantly decreased ST segment depression magnitude and prolonged total exercise time compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: